Buonerba C - Search Results

1

Testicular cancer from diagnosis to epigenetic factors.

Boccellino M, Vanacore D, Zappavigna S, Cavaliere C, Rossetti S, D'Aniello C, Chieffi P, Amler E, Buonerba C, Di Lorenzo G, Di Franco R, Izzo A, Piscitelli R, Iovane G, Muto P, Botti G, Perdonà S, Caraglia M, Facchini G. Boccellino M, et al. Among authors: buonerba c. Oncotarget. 2017 Sep 18;8(61):104654-104663. doi: 10.18632/oncotarget.20992. eCollection 2017 Nov 28. Oncotarget. 2017. PMID: 29262668 Free PMC article. Review.

2

Ten-year adjuvant treatment with somatostatin analogs in a patient with atypical carcinoid of the lung.

Buonerba C, Gallo C, Di Lorenzo G, Romeo V, Marinelli A. Buonerba C, et al. Anticancer Drugs. 2010 Apr;21(4):465-8. doi: 10.1097/CAD.0b013e32833688a2. Anticancer Drugs. 2010. PMID: 20075713

3

Castration-resistant prostate cancer: current and emerging treatment strategies.

Di Lorenzo G, Buonerba C, Autorino R, De Placido S, Sternberg CN. Di Lorenzo G, et al. Among authors: buonerba c. Drugs. 2010 May 28;70(8):983-1000. doi: 10.2165/10898600-000000000-00000. Drugs. 2010. PMID: 20481655 Review.

4

Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme?

Gallo C, Buonerba C, Di Lorenzo G, Romeo V, De Placido S, Marinelli A. Gallo C, et al. Among authors: buonerba c. J Neurooncol. 2010 Nov;100(2):311-9. doi: 10.1007/s11060-010-0168-y. Epub 2010 Jun 17. J Neurooncol. 2010. PMID: 20556481

5

Docetaxel rechallenge in castration-resistant prostate cancer: scientific legitimacy of common clinical practice.

Buonerba C, Palmieri G, Di Lorenzo G. Buonerba C, et al. Eur Urol. 2010 Oct;58(4):636-7. doi: 10.1016/j.eururo.2010.06.025. Epub 2010 Jun 23. Eur Urol. 2010. PMID: 20580484 No abstract available.

6

Kidney cancer: overall survival is an unsuitable primary end point.

Di Lorenzo G, Buonerba C. Di Lorenzo G, et al. Among authors: buonerba c. Nat Rev Urol. 2010 Jul;7(7):367-8. doi: 10.1038/nrurol.2010.84. Nat Rev Urol. 2010. PMID: 20616795

7

Sipuleucel-T for prostate cancer: the immunotherapy era has commenced.

Buonerba C, Ferro M, Di Lorenzo G. Buonerba C, et al. Expert Rev Anticancer Ther. 2011 Jan;11(1):25-8. doi: 10.1586/era.10.180. Expert Rev Anticancer Ther. 2011. PMID: 21166508 Review.

8

Toxicities of targeted therapy and their management in kidney cancer.

Di Lorenzo G, Porta C, Bellmunt J, Sternberg C, Kirkali Z, Staehler M, Joniau S, Montorsi F, Buonerba C. Di Lorenzo G, et al. Among authors: buonerba c. Eur Urol. 2011 Apr;59(4):526-40. doi: 10.1016/j.eururo.2011.01.002. Epub 2011 Jan 14. Eur Urol. 2011. PMID: 21277078 Review.

9

Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.

Buonerba C, Federico P, D'Aniello C, Rescigno P, Cavaliere C, Puglia L, Ferro M, Altieri V, Perdonà S, De Placido S, Di Lorenzo G. Buonerba C, et al. Cancer Chemother Pharmacol. 2011 Jun;67(6):1455-61. doi: 10.1007/s00280-011-1594-z. Epub 2011 Mar 2. Cancer Chemother Pharmacol. 2011. PMID: 21365219 Clinical Trial.

10

An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples.

Di Lorenzo G, Casciano R, Malangone E, Buonerba C, Sherman S, Willet J, Wang X, Liu Z, De Placido S. Di Lorenzo G, et al. Among authors: buonerba c. Expert Opin Pharmacother. 2011 Jul;12(10):1491-7. doi: 10.1517/14656566.2011.587119. Epub 2011 May 21. Expert Opin Pharmacother. 2011. PMID: 21599551 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

185 results

Search Page